A carregar...
Data showing the circumvention of oxaliplatin resistance by vatalanib in colon cancer
We have recently reported that vatalanib, an orally active small molecule multi-tyrosine kinase inhibitor (Hess-Stumpp et al., 2005 [1]), can sensitize multidrug resistant (MDR) colon cancer cells to chemotherapy under hypoxia by inhibiting two MDR transporters ABCB1 and ABCG2 (To et al., 2015 [2])....
Na minha lista:
| Publicado no: | Data Brief |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Elsevier
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4789311/ https://ncbi.nlm.nih.gov/pubmed/27014726 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.dib.2016.02.064 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|